Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Song, Ju Han | - |
dc.contributor.author | Cho, Kyung-Min | - |
dc.contributor.author | Kim, Hyeoung-Joon | - |
dc.contributor.author | Kim, Yeo-Kyeoung | - |
dc.contributor.author | Kim, Nan Young | - |
dc.contributor.author | Kim, Hee-Je | - |
dc.contributor.author | Lee, Tae-Hyang | - |
dc.contributor.author | Hwang, Seung Yong | - |
dc.contributor.author | Kim, Tae Sung | - |
dc.date.accessioned | 2021-09-04T14:44:58Z | - |
dc.date.available | 2021-09-04T14:44:58Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2015-07 | - |
dc.identifier.issn | 1021-335X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/93120 | - |
dc.description.abstract | Although acute myeloid leukemia (AML) exhibits diverse responses to chemotherapy, patients harboring the 48;21) translocation are part of a favorable risk group. However, the reason why this subgroup is more responsive to cytarabine-based therapy has not been elucidated. In the present study, we analyzed expression levels of cytarabine metabolism-related genes in patients diagnosed with AML with or without t(8;21) and investigated their correlation with clinical outcomes after cytarabine-based therapy. Among the 8 genes studied, expression of the concentrative nucleoside transporter 3 (CNT3) gene was significantly higher in t(8;21)positive patients compared to the others in the test population and the validation cohort (P<0.001 in Mann-Whitney U test; P<0.002 in Pearson's correlation analysis). Additionally, in both multivariate and univariate analyses, t(8;21)-positive patients categorized in a higher CNT3 expression tertile had longer disease-free survival [hazard ratio (HR), 0.117; 95% confidence interval (CI), 0.025-0.557; P=0.008] and overall survival (HR, 0.062; 95% CI, 0.007-0.521; P=0.010) compared to t(8;21)-positive patients in a lower CNT3 expression tertile. Notably, these trends did not occur in t(8;21)-negative patients. Our results demonstrate that CNT3 expression is associated with overall favorable outcomes and is predictive of clinical outcomes in AML patients with t(8;21). This suggests that CNT3 expression can be used to optimize treatment strategies for AML patients. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.subject | HIGH-DOSE CYTARABINE | - |
dc.subject | CHRONIC LYMPHOCYTIC-LEUKEMIA | - |
dc.subject | GENE-EXPRESSION SIGNATURES | - |
dc.subject | LONG-TERM SURVIVAL | - |
dc.subject | DEOXYCYTIDINE KINASE | - |
dc.subject | CYTOSINE-ARABINOSIDE | - |
dc.subject | CANCER-CHEMOTHERAPY | - |
dc.subject | REMISSION DURATION | - |
dc.subject | MOLECULAR SUBTYPES | - |
dc.subject | CYTIDINE DEAMINASE | - |
dc.title | Concentrative nucleoside transporter 3 as a prognostic indicator for favorable outcome of t(8;21)-positive acute myeloid leukemia patients after cytarabine-based chemotherapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Tae Sung | - |
dc.identifier.doi | 10.3892/or.2015.3959 | - |
dc.identifier.scopusid | 2-s2.0-84930020011 | - |
dc.identifier.wosid | 000356645100059 | - |
dc.identifier.bibliographicCitation | ONCOLOGY REPORTS, v.34, no.1, pp.488 - 494 | - |
dc.relation.isPartOf | ONCOLOGY REPORTS | - |
dc.citation.title | ONCOLOGY REPORTS | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 488 | - |
dc.citation.endPage | 494 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | HIGH-DOSE CYTARABINE | - |
dc.subject.keywordPlus | CHRONIC LYMPHOCYTIC-LEUKEMIA | - |
dc.subject.keywordPlus | GENE-EXPRESSION SIGNATURES | - |
dc.subject.keywordPlus | LONG-TERM SURVIVAL | - |
dc.subject.keywordPlus | DEOXYCYTIDINE KINASE | - |
dc.subject.keywordPlus | CYTOSINE-ARABINOSIDE | - |
dc.subject.keywordPlus | CANCER-CHEMOTHERAPY | - |
dc.subject.keywordPlus | REMISSION DURATION | - |
dc.subject.keywordPlus | MOLECULAR SUBTYPES | - |
dc.subject.keywordPlus | CYTIDINE DEAMINASE | - |
dc.subject.keywordAuthor | acute myeloid leukemia | - |
dc.subject.keywordAuthor | CNT3 | - |
dc.subject.keywordAuthor | cytarabine | - |
dc.subject.keywordAuthor | t(8 | - |
dc.subject.keywordAuthor | 21) translocation | - |
dc.subject.keywordAuthor | prognosis | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.